Waratah Capital Advisors Ltd. Reduces Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Waratah Capital Advisors Ltd. lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 36.0% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,203 shares of the medical research company’s stock after selling 16,452 shares during the period. Waratah Capital Advisors Ltd.’s holdings in Thermo Fisher Scientific were worth $17,249,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the company. Otter Creek Advisors LLC bought a new stake in shares of Thermo Fisher Scientific during the first quarter valued at about $2,309,000. Fort Sheridan Advisors LLC raised its position in Thermo Fisher Scientific by 69.4% in the first quarter. Fort Sheridan Advisors LLC now owns 2,051 shares of the medical research company’s stock worth $1,211,000 after acquiring an additional 840 shares in the last quarter. Capital Advisors Ltd. LLC raised its position in Thermo Fisher Scientific by 25.0% in the first quarter. Capital Advisors Ltd. LLC now owns 714 shares of the medical research company’s stock worth $422,000 after acquiring an additional 143 shares in the last quarter. Meitav Dash Investments Ltd. raised its position in Thermo Fisher Scientific by 479.6% in the first quarter. Meitav Dash Investments Ltd. now owns 48,648 shares of the medical research company’s stock worth $28,529,000 after acquiring an additional 40,254 shares in the last quarter. Finally, Banco Santander S.A. raised its position in Thermo Fisher Scientific by 6.1% in the first quarter. Banco Santander S.A. now owns 15,280 shares of the medical research company’s stock worth $9,025,000 after acquiring an additional 882 shares in the last quarter. Hedge funds and other institutional investors own 87.48% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on TMO shares. SVB Leerink boosted their price target on shares of Thermo Fisher Scientific from $630.00 to $650.00 and gave the stock an “outperform” rating in a research report on Friday, July 29th. Barclays boosted their price objective on Thermo Fisher Scientific from $630.00 to $685.00 and gave the stock an “overweight” rating in a report on Monday, August 1st. Morgan Stanley boosted their price objective on Thermo Fisher Scientific from $670.00 to $678.00 and gave the stock an “overweight” rating in a report on Friday, July 29th. Finally, Wells Fargo & Company cut Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and lowered their target price for the company from $605.00 to $525.00 in a research note on Monday, April 25th. One research analyst has rated the stock with a sell rating, two have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $661.08.

Thermo Fisher Scientific Trading Up 0.0 %

NYSE:TMO traded up $0.26 during mid-day trading on Friday, hitting $590.26. The company had a trading volume of 982,467 shares, compared to its average volume of 1,459,510. Thermo Fisher Scientific Inc. has a fifty-two week low of $497.83 and a fifty-two week high of $672.34. The business’s fifty day moving average is $549.03 and its two-hundred day moving average is $557.79. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.13 and a current ratio of 1.65. The firm has a market cap of $231.06 billion, a P/E ratio of 31.41, a P/E/G ratio of 1.84 and a beta of 0.83.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last released its earnings results on Thursday, July 28th. The medical research company reported $5.51 earnings per share for the quarter, beating the consensus estimate of $4.92 by $0.59. The firm had revenue of $10.97 billion for the quarter, compared to analyst estimates of $9.95 billion. Thermo Fisher Scientific had a return on equity of 24.36% and a net margin of 17.37%. The company’s quarterly revenue was up 18.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $5.60 earnings per share. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 22.92 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 14th. Stockholders of record on Thursday, September 15th will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a dividend yield of 0.20%. The ex-dividend date of this dividend is Wednesday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 6.39%.

Insider Transactions at Thermo Fisher Scientific

In other news, COO Michel Lagarde sold 13,030 shares of the firm’s stock in a transaction dated Friday, May 27th. The stock was sold at an average price of $565.04, for a total transaction of $7,362,471.20. Following the sale, the chief operating officer now owns 15,758 shares of the company’s stock, valued at $8,903,900.32. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $589.76, for a total value of $5,897,600.00. Following the sale, the chief executive officer now owns 183,373 shares in the company, valued at approximately $108,146,060.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Michel Lagarde sold 13,030 shares of the business’s stock in a transaction that occurred on Friday, May 27th. The shares were sold at an average price of $565.04, for a total value of $7,362,471.20. Following the completion of the sale, the chief operating officer now owns 15,758 shares in the company, valued at approximately $8,903,900.32. The disclosure for this sale can be found here. Insiders have sold a total of 50,994 shares of company stock valued at $29,033,170 over the last 90 days. 0.43% of the stock is owned by company insiders.

About Thermo Fisher Scientific

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Articles

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.